New antibiotics for the treatment of nonfermenting Gram-negative bacteria.
Journal
Current opinion in infectious diseases
ISSN: 1473-6527
Titre abrégé: Curr Opin Infect Dis
Pays: United States
ID NLM: 8809878
Informations de publication
Date de publication:
01 12 2021
01 12 2021
Historique:
pubmed:
13
10
2021
medline:
15
12
2021
entrez:
12
10
2021
Statut:
ppublish
Résumé
To discuss the current literature on novel agents for the treatment of carbapenem-resistant nonfermenting Gram-negative bacteria (NF-GNB) infections. Some novel agents have recently become available that are expected to replace classical polymyxins as the first-line options for the treatment of carbapenem-resistant NF-GNB infections. In this narrative review, we provide a brief overview of the differential activity of various recently approved agents against NF-GNB most encountered in the daily clinical practice, as well as the results from phase-3 randomized clinical trials and large postapproval observational studies, with special focus on NF-GNB. Since resistance to novel agents has already been reported, the use of novel agents needs to be optimized, based on their differential activity (not only in terms of targeted bacteria, but also of resistance determinants), the local microbiological epidemiology, and the most updated pharmacokinetic/pharmacodynamic data. Large real-life experiences remain of crucial importance for further refining the optimal treatment of NF-GNB infections in the daily clinical practice.
Identifiants
pubmed: 34637210
doi: 10.1097/QCO.0000000000000757
pii: 00001432-202112000-00018
pmc: PMC9914177
doi:
Substances chimiques
Anti-Bacterial Agents
0
Carbapenems
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
701-709Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Gajdacs M, Burian K, Terhes G. Resistance levels and epidemiology of non-fermenting Gram-negative bacteria in urinary tract infections of inpatients and outpatients (RENFUTI): a 10-year epidemiological snapshot. Antibiotics 2019; 8:143.
Giacobbe DR, Mikulska M, Viscoli C. Recent advances in the pharmacological management of infections due to multidrug-resistant Gram-negative bacteria. Expert Rev Clin Pharmacol 2018; 11:1219–1236.
Karaiskos I, Lagou S, Pontikis K, et al. The ‘old’ and the ‘new’ antibiotics for MDR Gram-negative pathogens: for whom, when, and how. Front Public Health 2019; 7:151.
Bassetti M, Peghin M, Vena A, Giacobbe DR. Treatment of infections due to MDR Gram-negative bacteria. Front Med 2019; 6:74.
Russo A, Bassetti M, Ceccarelli G, et al. Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study. J Infect 2019; 79:130–138.
Karaiskos I, Souli M, Galani I, Giamarellou H. Colistin: still a lifesaver for the 21st century? Expert Opin Drug Metab Toxicol 2017; 13:59–71.
Kaye KS, Pogue JM, Tran TB, et al. Agents of last resort: polymyxin resistance. Infect Dis Clin N Am 2016; 30:391–414.
Bassetti M, Labate L, Russo C, et al. Therapeutic options for difficult-to-treat Acinetobacter baumannii infections: a 2020 perspective. Expert Opin Pharmacother 2021; 22:167–177.
Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Antiinfective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 2019; 39:10–39.
Paul M, Zusman O, Leibovici L. Meta-analysis of polymyxin use in patients. Adv Exp Med Biol 2019; 1145:143–153.
Ehmann DE, Jahic H, Ross PL, et al. Avibactam is a covalent, reversible, nonbeta-lactam beta-lactamase inhibitor. Proc Natl Acad Sci USA 2012; 109:11663–11668.
van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation beta-lactam/beta-lactamase inhibitor combinations. Clin Infect Dis 2016; 63:234–241.
Bassetti M, Di Pilato V, Giani T, et al. Treatment of severe infections due to metallo-beta-lactamases-producing Gram-negative bacteria. Future Microbiol 2020; 15:1489–1505.
Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother 2014; 15:1351–1370.
Sader HS, Castanheira M, Flamm RK, et al. Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S medical centers in 2012. Antimicrob Agents Chemother 2014; 58:1684–1692.
Kuo SC, Wang YC, Tan MC, et al. In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-nonsusceptible Gram-negative bacilli from Taiwan. J Antimicrob Chemother 2021; 76:2071–2078.
Testa R, Canton R, Giani T, et al. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates. Int J Antimicrob Agents 2015; 45:641–646.
Ehmann DE, Jahic H, Ross PL, et al. Kinetics of avibactam inhibition against Class A, C, and D beta-lactamases. J Biol Chem 2013; 288:27960–27971.
Falcone M, Paterson D. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections. J Antimicrob Chemother 2016; 71:2713–2722.
Huband MD, Castanheira M, Flamm RK, et al. In vitro activity of ceftazidime-avibactam against contemporary pseudomonas aeruginosa isolates from U.S Medical Centers by Census Region, 2014. Antimicrob Agents Chemother 2016; 60:2537–2541.
Sader HS, Castanheira M, Mendes RE, et al. Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S medical centers in 2012 and 2013. Antimicrob Agents Chemother 2015; 59:3656–3659.
Nguyen L, Garcia J, Gruenberg K, MacDougall C. Multidrug-resistant pseudomonas infections: hard to treat, but hope on the horizon? Curr Infect Dis Rep 2018; 20:23.
Livermore DM, Meunier D, Hopkins KL, et al. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK. J Antimicrob Chemother 2018; 73:648–657.
Lin Q, Zou H, Chen X, et al. Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro. BMC Microbiol 2021; 21:60.
Moriceau C, Eveillard M, Lemarie C, et al. Stenotrophomonas maltophilia susceptibility to ceftazidime-avibactam combination versus ceftazidime alone. Med Mal Infect 2020; 50:305–307.
Van Dalem A, Herpol M, Echahidi F, et al. In vitro susceptibility of Burkholderia cepacia complex isolated from cystic fibrosis patients to ceftazidime-avibactam and ceftolozane-tazobactam. Antimicrob Agents Chemother 2018; 62:e00590-18.
Carmeli Y, Armstrong J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 2016; 16:661–673.
Mazuski JE, Gasink LB, Armstrong J, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis 2016; 62:1380–1389.
Torres A, Zhong N, Pachl J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 noninferiority trial. Lancet Infect Dis 2018; 18:285–295.
Wagenlehner FM, Sobel JD, Newell P, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a Phase 3 randomized trial program. Clin Infect Dis 2016; 63:754–762.
Giacobbe DR, Bassetti M, De Rosa FG, et al. Ceftolozane/tazobactam: place in therapy. Expert Rev Anti Infect Ther 2018; 16:307–320.
Moya B, Zamorano L, Juan C, et al. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa . Antimicrob Agents Chemother 2010; 54:3933–3937.
Moya B, Beceiro A, Cabot G, et al. Pan-beta-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities. Antimicrob Agents Chemother 2012; 56:4771–4778.
Castanheira M, Mills JC, Farrell DJ, Jones RN. Mutation-driven beta-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from US hospitals. Antimicrob Agents Chemother 2014; 58:6844–6850.
Moya B, Zamorano L, Juan C, et al. Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob Agents Chemother 2010; 54:1213–1217.
Giani T, Arena F, Pollini S, et al. Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers. J Antimicrob Chemother 2018; 73:664–671.
Grupper M, Sutherland C, Nicolau DP. Multicenter evaluation of ceftazidime-avibactam and ceftolozane-tazobactam inhibitory activity against meropenem-nonsusceptible pseudomonas aeruginosa from blood, respiratory tract, and wounds. Antimicrob Agents Chemother 2017; 61:e00875-17.
Karlowsky JA, Lob SH, Young K, et al. Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections - SMART United States. BMC Microbiol 2021; 21:74.
Pfaller MA, Bassetti M, Duncan LR, Castanheira M. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme. J Antimicrob Chemother 2017; 72:1386–1395.
Pfaller MA, Shortridge D, Sader HS, et al. Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program. Braz J Infect Dis 2017; 21:627–637.
Seifert H, Korber-Irrgang B, Kresken M, German Ceftolozane/Tazobactam Study G. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany. Int J Antimicrob Agents 2018; 51:227–234.
Shortridge D, Castanheira M, Pfaller MA, Flamm RK. Ceftolozane-tazobactam activity against pseudomonas aeruginosa clinical isolates from U.S Hospitals: Report from the PACTS Antimicrobial Surveillance Program 2012 to 2015. Antimicrob Agents Chemother 2017; 61: e00465-17.
Shortridge D, Pfaller MA, Castanheira M, Flamm RK. Antimicrobial activity of ceftolozane-tazobactam tested against enterobacteriaceae and pseudomonas aeruginosa with various resistance patterns isolated in U.S Hospitals (2013–2016) as part of the surveillance program: program to assess ceftolozane-tazobactam susceptibility. Microb Drug Resist 2018; 24:563–577.
Livermore DM, Mushtaq S, Meunier D, et al. Activity of ceftolozane/tazobactam against surveillance and ’problem’ Enterobacteriaceae, Pseudomonas aeruginosa and nonfermenters from the British Isles. J Antimicrob Chemother 2017; 72:2278–2289.
Mazer DM, Young C, Kalikin LM, et al. In vitro activity of ceftolozane-tazobactam and other antimicrobial agents against Burkholderia cepacia Complex and Burkholderia gladioli. Antimicrob Agents Chemother 2017; 61:e00766-17.
Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, Phase 3 Trial (ASPECT-cIAI). Clin Infect Dis 2015; 60:1462–1471.
Wagenlehner FM, Umeh O, Steenbergen J, et al. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 2015; 385:1949–1956.
Kollef MH, Novacek M, Kivistik U, et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, noninferiority trial. Lancet Infect Dis 2019; 19:1299–1311.
Lucasti C, Vasile L, Sandesc D, et al. Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection. Antimicrob Agents Chemother 2016; 60:6234–6243.
Blomquist KC, Nix DE. A critical evaluation of newer beta-lactam antibiotics for treatment of pseudomonas aeruginosa infections. Ann Pharmacother 2021; 55:1010–1024.
Karlowsky JA, Lob SH, Raddatz J, et al. In vitro activity of imipenem/relebactam and ceftolozane/tazobactam against clinical isolates of Gram-Negative Bacilli with difficult-to-treat resistance and multidrug-resistant phenotypes - SMART United States. Clin Infect Dis 2021; 72:2112–2120.
Livermore DM, Warner M, Mushtaq S. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa . J Antimicrob Chemother 2013; 68:2286–2290.
Young K, Painter RE, Raghoobar SL, et al. In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa . BMC Microbiol 2019; 19:150.
Zhanel GG, Lawrence CK, Adam H, et al. Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-beta-lactamase inhibitor combinations. Drugs 2018; 78:65–98.
Karlowsky JA, Lob SH, Kazmierczak KM, et al. In vitro activity of imipenem-relebactam against clinical isolates of Gram-negative bacilli isolated in hospital laboratories in the United States as Part of the SMART 2016 Program. Antimicrob Agents Chemother 2018; 62:e00169-18.
Lapuebla A, Abdallah M, Olafisoye O, et al. Activity of imipenem with relebactam against Gram-negative pathogens from New York City. Antimicrob Agents Chemother 2015; 59:5029–5031.
Lob SH, Hoban DJ, Sahm DF, Badal RE. Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii. Int J Antimicrob Agents 2016; 47:317–323.
Titov I, Wunderink RG, Roquilly A, et al. A Randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem/cilastatin/relebactam versus piperacillin/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 Study). Clin Infect Dis 2020; doi: 10.1093/cid/ciaa803.
doi: 10.1093/cid/ciaa803
Motsch J, Murta de Oliveira C, Stus V, et al. RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clin Infect Dis 2020; 70:1799–1808.
Giacobbe DR, Ciacco E, Girmenia C, et al. Evaluating cefiderocol in the treatment of multidrug-resistant Gram-Negative Bacilli: a review of the emerging data. Infect Drug Resist 2020; 13:4697–4711.
Ito A, Nishikawa T, Matsumoto S, et al. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa . Antimicrob Agents Chemother 2016; 60:7396–7401.
Sato T, Yamawaki K. Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. Clin Infect Dis 2019; 69:S538–S543.
Zhanel GG, Golden AR, Zelenitsky S, et al. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant Gram-Negative Bacilli. Drugs 2019; 79:271–289.
Hackel MA, Tsuji M, Yamano Y, et al. In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-Negative Bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study). Antimicrob Agents Chemother 2017; 61:e00093-17.
Hackel MA, Tsuji M, Yamano Y, et al. In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016. Antimicrob Agents Chemother 2018; 62:e01968-17.
Karlowsky JA, Hackel MA, Tsuji M, et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-Negative Bacilli isolated by clinical laboratories in North America and Europe in 2015–2016: SIDERO-WT. Int J Antimicrob Agents 2019; 53:456–466.
Kazmierczak KM, Tsuji M, Wise MG, et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-nonsusceptible Gram-negative bacilli, including serine carbapenemase- and metallo-beta-lactamase-producing isolates (SIDERO-WT-2014 Study). Int J Antimicrob Agents 2019; 53:177–184.
Biagi M, Vialichka A, Jurkovic M, et al. Activity of cefiderocol alone and in combination with levofloxacin, minocycline, polymyxin B, or trimethoprim-sulfamethoxazole against multidrug-resistant Stenotrophomonas maltophilia . Antimicrob Agents Chemother 2020; 64:e00297-20.
Delgado-Valverde M, Conejo MDC, Serrano L, et al. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia . J Antimicrob Chemother 2020; 75:1840–1849.
Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 2021; 21:226–240.
Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, noninferiority trial. Lancet Infect Dis 2021; 21:213–225.
Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, noninferiority trial. Lancet Infect Dis 2018; 18:1319–1328.
Alosaimy S, Abdul-Mutakabbir JC, Kebriaei R, et al. Evaluation of eravacycline: a novel fluorocycline. Pharmacotherapy 2020; 40:221–238.
Bassetti M, Vena A, Battaglini D, et al. The role of new antimicrobials for Gram-negative infections in daily clinical practice. Curr Opin Infect Dis 2020; 33:495–500.
Seifert H, Stefanik D, Sutcliffe JA, Higgins PG. In-vitro activity of the novel fluorocycline eravacycline against carbapenem nonsusceptible Acinetobacter baumannii . Int J Antimicrob Agents 2018; 51:62–64.
Morrissey I, Olesky M, Hawser S, et al. In vitro activity of eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017. Antimicrob Agents Chemother 2020; 64:e01699-19.
Sutcliffe JA, O’Brien W, Fyfe C, Grossman TH. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother 2013; 57:5548–5558.
Solomkin J, Evans D, Slepavicius A, et al. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg 2017; 152:224–232.
Solomkin JS, Gardovskis J, Lawrence K, et al. IGNITE4: results of a Phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections. Clin Infect Dis 2019; 69:921–929.
Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S. [cited 13 Jun 2021]. Available at: https://www.globenewswire.com/news-release/2021/01/26/2164231/0/en/Entasis-Therapeutics-Announces-Sulbactam-Durlobactam-Expanded-Access-Program-for-Patients-in-the-U-S.html .
Theuretzbacher U, Bush K, Harbarth S, et al. Critical analysis of antibacterial agents in clinical development. Nat Rev Microbiol 2020; 18:286–298.
Choby JE, Ozturk T, Satola SW, et al. Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens. Lancet Infect Dis 2021; 21:597–598.
Kristof K, Adamkova V, Adler A, et al. In vitro activity of ceftazidime-avibactam and comparators against Enterobacterales and Pseudomonas aeruginosa isolates from Central Europe and Israel, 2014–2017 and 2018. Diagn Microbiol Infect Dis 2021; 101:115420.
Endimiani A, Ramette A, Rhoads DD, Jacobs MR. The evolving role of the clinical microbiology laboratory in identifying resistance in Gram-negative bacteria: an update. Infect Dis Clin North Am 2020; 34:659–676.
Giacobbe DR, Giani T, Bassetti M, et al. Rapid microbiological tests for bloodstream infections due to multidrug resistant Gram-negative bacteria: therapeutic implications. Clin Microbiol Infect 2020; 26:713–722.
Bavaro DF, Belati A, Diella L, et al. Cefiderocol-based combination therapy for ‘Difficult-to-Treat’ Gram-negative severe infections: real-life case series and future perspectives. Antibiotics 2021; 10:652.
Falcone M, Tiseo G, Nicastro M, et al. Cefiderocol as rescue therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative infections in intensive care unit patients. Clin Infect Dis 2021; 72:2021–2024.
Oliva A, Ceccarelli G, De Angelis M, et al. Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii. J Glob Antimicrob Resist 2020; 23:292–296.
Alosaimy S, Molina KC, Claeys KC, et al. Early experience with eravacycline for complicated infections. Open Forum Infect Dis 2020; 7:ofaa071.
Balandin B, Ballesteros D, Ruiz de Luna R, et al. Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients. Int J Antimicrob Agents 2021; 57:106270.
Bassetti M, Castaldo N, Cattelan A, et al. Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience. Int J Antimicrob Agents 2019; 53:408–415.
Castan B, Akrich B, Levy-Bachelot L, et al. Real-world evaluation of ceftolozane/tazobactam therapy and clinical outcomes in France. Infect Dis Now 2021; doi: 10.1016/j.idnow.2021.05.003.
doi: 10.1016/j.idnow.2021.05.003
Cultrera R, Libanore M, Barozzi A, et al. Ceftolozane/tazobactam and ceftazidime/avibactam for multidrug-resistant Gram-negative infections in immunocompetent patients: a single-center retrospective study. Antibiotics 2020; 9:640.
Diaz-Canestro M, Perianez L, Mulet X, et al. Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa : experience from the Balearic Islands. Eur J Clin Microbiol Infect Dis 2018; 37:2191–2200.
Escola-Verge L, Pigrau C, Los-Arcos I, et al. Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections. Infection 2018; 46:461–468.
Gallagher JC, Satlin MJ, Elabor A, et al. Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: a multicenter study. Open Forum Infect Dis 2018; 5:ofy280.
Haidar G, Philips NJ, Shields RK, et al. Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance. Clin Infect Dis 2017; 65:110–120.
Hart DE, Gallagher JC, Puzniak LA, et al. A multicenter evaluation of ceftolozane/tazobactam treatment outcomes in immunocompromised patients with multidrug-resistant Pseudomonas aeruginosa infections. Open Forum Infect Dis 2021; 8:ofab089.
Jorgensen SCJ, Trinh TD, Zasowski EJ, et al. Real-world experience with ceftazidime-avibactam for multidrug-resistant gram-negative bacterial infections. Open Forum Infect Dis 2019; 6:ofz522.
Jorgensen SCJ, Trinh TD, Zasowski EJ, et al. Real-world experience with ceftolozane-tazobactam for multidrug-resistant Gram-negative bacterial infections. Antimicrob Agents Chemother 2020; 64:e02291-19.
Munita JM, Aitken SL, Miller WR, et al. Multicenter evaluation of ceftolozane/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa . Clin Infect Dis 2017; 65:158–161.
Pogue JM, Kaye KS, Veve MP, et al. Ceftolozane/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa . Clin Infect Dis 2020; 71:304–310.
Rodriguez-Nunez O, Perianez-Parraga L, Oliver A, et al. Higher MICs (>2 mg/L) predict 30-day mortality in patients with lower respiratory tract infections caused by multidrug- and extensively drug-resistant pseudomonas aeruginosa treated with ceftolozane/tazobactam. Open Forum Infect Dis 2019; 6:ofz416.
Sacha GL, Neuner EA, Athans V, et al. Retrospective evaluation of the use of ceftolozane/tazobactam at a large Academic Medical Center. Infect Dis Clin Pract 2017; 25:305–309.
Vena A, Giacobbe DR, Castaldo N, et al. Clinical experience with ceftazidime-avibactam for the treatment of infections due to multidrug-resistant Gram-negative bacteria other than carbapenem-resistant Enterobacterales. Antibiotics 2020; 9:71.
Xipell M, Paredes S, Fresco L, et al. Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa . J Glob Antimicrob Resist 2018; 13:165–170.
Zhanel GG, Dhami R, Baxter M, et al. Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry. J Glob Antimicrob Resist 2021; 25:346–350.